Physician profile
Michelle Hall
NPI 1053662247
$3,873.67
in general payments reported to CMS, 2019-2025
28 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $967 · 2022: $485 · 2023: $1,048 · 2024: $1,250 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,422.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,422.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,067.77 | 2021-2025 | |
| Novo Nordisk INC | $429.24 | 2021-2024 | Wegovy |
| Pfizer INC. | $352.66 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $276.64 | 2021-2024 | Jardiance |
| Exact Sciences Corporation | $271.95 | 2023-2024 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $158.99 | 2023-2024 | Rexulti |
| Amgen INC. | $136.18 | 2021-2024 | Otezla, Repatha |
| Kowa Pharmaceuticals America, INC. | $111.91 | 2021-2023 | Seglentis, Livalo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $105.50 | 2022-2024 | Caplyta |
| Lilly USA, LLC | $105.04 | 2021-2024 | Mounjaro |
| Novartis Pharmaceuticals Corporation | $88.15 | 2022-2023 | |
| Astellas Pharma US INC | $87.48 | 2024 | Veozah |
| Amarin Pharma, INC. | $84.63 | 2021 | |
| Almatica Pharma LLC | $80.20 | 2021-2024 | Loreev Xr |
| Abbott Laboratories | $68.85 | 2023-2024 | Freestyle Libre 3 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $62.00 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $57.40 | 2021-2024 | Airsupra |
| Gebauer Company | $47.14 | 2025 | |
| Glaxosmithkline, LLC. | $41.26 | 2022-2023 | Shingrix, Arexvy |
| Eisai INC. | $40.94 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $36.04 | 2022 | |
| Merck Sharp & Dohme LLC | $34.92 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.25 | 2022-2023 | Cycloset |
| Neurelis, INC. | $31.23 | 2022 | |
| Jazz Pharmaceuticals INC. | $19.72 | 2021 | |
| Lundbeck LLC | $16.42 | 2024 | Rexulti |
| Dexcom, INC. | $16.21 | 2025 | Dexcom G6 Transmitter |
| Hikma Pharmaceuticals USA | $13.95 | 2023 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.